Aarti Drugs Q1 Results FY27: What to Expect
- June 30, 2026
- Posted by: Kunal Singla
- Category: News
Aarti Drugs Q1 Results FY27: Revenue Rs 551 Cr (+5.7% YoY) | PAT Rs 74 Cr (+50.0% YoY). Uniresearch Q1 results preview.
This Aarti Drugs Q1 results preview is based on Screener.in consolidated quarterly financials for the Q1 FY26 base quarter, with the Uniresearch trailing-growth model applied to project the Q1 FY27 estimate. Aarti Drugs reported Revenue of Rs 521 Cr and PAT of Rs 49 Cr in Q1 FY26, forming the base for the Aarti Drugs Q1 Results FY27 forecast of Rs 551 Cr Revenue and Rs 74 Cr PAT. Prepared by Kunal Singla, Associate Director.
Click Here – Get Free Investment Predictions
Aarti Drugs Q1 Results FY27: Uniresearch Prediction
| Metric | Q1 FY26 Actual | Q1 FY27 Uniresearch Prediction | YoY Change |
|---|---|---|---|
| Revenue (Rs Cr) | 521 | 551 | +5.7% |
| PAT (Rs Cr) | 49 | 74 | +50.0% |
Source: Q1 FY26 actuals from Screener.in. Q1 FY27 prediction for Aarti Drugs applies Uniresearch trailing growth rates (Revenue +5.7%, PAT +50.0%) to Q1 FY26 verified actuals.
Track Aarti Drugs Live on Univest Screener
Aarti Drugs Q1 Results FY27 Preview: Expectations, Results Date and Latest News
The Aarti Drugs Q1 results expectations for FY27 point to Revenue of Rs 551 Cr (+5.7% YoY) and PAT of Rs 74 Cr (+50.0% YoY), based on the Aarti Drugs Q1 Results FY27 Uniresearch estimate. These Aarti Drugs Q1 results expectations assume the growth trajectory from Q1 FY26 continues into Q1 FY27, supported by sector tailwinds in pharmaceuticals. Investors can use this Aarti Drugs Q1 results preview as a directional reference ahead of the official result declaration.
The Aarti Drugs Q1 results date is not yet officially announced. Typically, Q1 results dates for NSE-listed companies are disclosed via a board meeting notice on the NSE or BSE filing portal, shortly after Q1 FY27 ends. For the latest news on Aarti Drugs Q1 results FY26-27, track the Univest Screener and NSE filing alerts. Once the Aarti Drugs Q1 results date is confirmed, compare actual Aarti Drugs results against this Aarti Drugs Q1 Results FY27 preview.
Q4 FY26 Performance: Context for the Aarti Drugs Q1 Results FY27 Preview
The Aarti Drugs Q1 Results FY27 preview is anchored on Q4 FY26 consolidated Revenue of Rs 632 Cr and PAT of Rs 45 Cr. These Q4 FY26 actuals, combined with Uniresearch trailing growth estimates, form the basis of the Q1 FY27 Uniresearch projection for Aarti Drugs projection.
The sequential comparison also provides useful context. Q4 FY26 Revenue of Rs 632 Cr reflects year-end cycles that may not repeat equally in Q1 FY27. The more meaningful benchmark is the year-on-year comparison against Q1 FY26 Revenue of Rs 521 Cr, where the Aarti Drugs Q1 results expectations target +5.7% growth.
Uniresearch Estimate Behind the Aarti Drugs Q1 Results FY27 Projection
The Q1 FY27 prediction for Aarti Drugs is derived from Uniresearch trailing analysis, which estimates Q1 FY27 Revenue growth of +5.7% and PAT growth of +50.0% YoY. These trailing rates are applied to Q1 FY26 actuals to arrive at the projection of Rs 551 Cr Revenue and Rs 74 Cr PAT.
The Q1 FY27 estimation methodology for Aarti Drugs applies full-year FY27 trailing growth rates (+5.7% Revenue, +50.0% PAT) uniformly to Q1 FY26 actuals. This approach assumes the quarterly trajectory broadly mirrors the full-year trend. Treat this Q1 results preview as a directional benchmark, not a guaranteed outcome.
Get Expert Stock Picks on Univest
Aarti Drugs Q1 Results FY27 Expectations: Key Watchpoints
Revenue vs the Uniresearch Estimate
Whether Aarti Drugs results deliver Revenue in line with the Rs 551 Cr Aarti Drugs Q1 Results FY27 Uniresearch estimate (+5.7% YoY). Q4 FY26 Revenue was Rs 632 Cr.
PAT Margin Sustainability
PAT of Rs 74 Cr (+50.0% YoY) is the Aarti Drugs Q1 Results FY27 Uniresearch estimate. Q4 FY26 PAT was Rs 45 Cr. Margin stability in Aarti Drugs results signals operating leverage.
Management Commentary and Full-Year FY27 Guidance
Beyond the headline Aarti Drugs Q1 results, management commentary will be watched for full-year FY27 guidance on revenue trajectory, margin direction, and capital allocation.
Risks to the Aarti Drugs Q1 Results FY27 Prediction
Below-Estimate Revenue Growth
If actual Aarti Drugs Q1 results Revenue underperforms the +5.7% growth target, the Rs 551 Cr Aarti Drugs Q1 Results FY27 prediction would be revised downward.
PAT Pressure from Costs or Provisions
One-time charges, elevated provisions, or margin headwinds could push Aarti Drugs results PAT below Rs 74 Cr in Q1 FY27.
External and Macro Environment
Macro risks including commodity price movements, rupee volatility, interest rate changes, and FII/DII sentiment shifts could create downside risk in Aarti Drugs results even if company-specific execution remains on track.
Aarti Drugs Q1 Results FY26-27: Sector Growth Drivers and Latest News
The latest news on Aarti Drugs Q1 results FY26-27 from a sector perspective shows that pharmaceuticals is navigating the following growth drivers heading into Q1 FY27. Investors tracking Aarti Drugs Q1 results should monitor these sector-level trends.
Domestic Formulation Growth
India’s domestic pharma market grows at 8-10% annually, led by chronic therapies.
Regulated Market Export Pipeline
USFDA-approved facilities and a growing ANDA pipeline offer incremental export revenues.
Use Univest Screener to Track Aarti Drugs Live
Aarti Drugs Q1 Results FY27: What to Expect
The Q1 FY27 Uniresearch projection of Aarti Drugs Revenue Rs 551 Cr and PAT Rs 74 Cr covers the complete Aarti Drugs Q1 results preview, including expectations, risks, and sector outlook. Track the Aarti Drugs Q1 results date confirmation on the Univest Screener for timely updates.
Once the Aarti Drugs results are declared, compare them against this Uniresearch preview to assess beat, meet, or miss. Access expert research and screener tools on Univest to stay updated.
Download the Univest iOS App or Univest Android App for live Aarti Drugs Q1 FY27 result alerts.
Disclaimer: Revenue and PAT actuals sourced from Screener.in consolidated quarterly financial data. Q1 FY27 projections are derived from Uniresearch trailing growth rates applied to Q1 FY26 actuals. These are Uniresearch trailing estimates, not guaranteed outcomes. Investments are subject to market risk. For educational purposes only. SEBI RA INH000013776.
Frequently Asked Questions on Aarti Drugs Q1 Results FY27
What is the Uniresearch prediction for Aarti Drugs Q1 Results FY27?
Ans. Uniresearch projects Q1 FY27 Revenue for Aarti Drugs at Rs 551 Cr (+5.7% YoY) and PAT at Rs 74 Cr (+50.0% YoY), based on trailing analysis of Q1 FY26 actuals (Revenue Rs 521 Cr, PAT Rs 49 Cr). This Q1 FY27 estimate for Aarti Drugs is directional, not a guaranteed outcome.
What are the Aarti Drugs Q1 Results FY27 expectations?
Ans. The Q1 FY27 expectations for Aarti Drugs are Revenue Rs 551 Cr (+5.7% YoY) and PAT Rs 74 Cr (+50.0% YoY), per the Uniresearch trailing-growth estimate. These Aarti Drugs Q1 results expectations are based on Q1 FY26 actuals from Screener.in.
What were the Q4 FY26 actuals behind the Aarti Drugs Q1 Results FY27 projection?
Ans. Q4 FY26 consolidated Revenue was Rs 632 Cr and PAT was Rs 45 Cr, serving as the most recent sequential reference for this Q1 FY27 preview of Aarti\ Drugs.
How reliable is the Aarti Drugs Q1 Results FY27 Uniresearch prediction?
Ans. The Q1 FY27 results preview for Aarti Drugs is a Uniresearch trailing projection, not a guaranteed outcome. Actual results may differ due to macro conditions, seasonal variation, and company-specific execution. Use the projection as a directional benchmark.
What base data is used for the Aarti Drugs Q1 Results FY27 Uniresearch projection?
Ans. The Aarti Drugs Q1 Results FY27 projection uses Q1 FY26 consolidated actuals (Revenue Rs 521 Cr, PAT Rs 49 Cr) from Screener.in, with trailing growth rates (+5.7% Revenue, +50.0% PAT) applied to derive the estimate.
What are the key risks to the Aarti Drugs Q1 Results FY27 estimate?
Ans. Key risks to the Q1 FY27 results of Aarti\ Drugs include usfda regulatory risk, us generic pricing erosion, and broader macro headwinds that could cause actual Aarti Drugs results to undershoot the Uniresearch Q1 results preview.
When will Aarti Drugs Q1 Results FY27 results be announced?
Ans. The Aarti Drugs Q1 results date has not been officially announced yet. Q1 FY27 results for NSE-listed companies are typically declared shortly after Q1 FY27 ends, with the Aarti Drugs Q1 results date disclosed via a board meeting notice on the NSE or BSE filing portal. Track the latest news on Aarti Drugs Q1 results FY26-27 on the Univest Screener for timely updates.
